Eli Lilly in Kinsale is the prime example of developments the president said the US should not have allowed to happen ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Scholar Rock Holding (SRRK – Research ...

Irish government mounts a St. Patrick’s Day diplomatic offensive to try and calm Trump anger at ‘massive’ trade surplus.

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...